(Q43989864)

28 November 2017

title

In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone (English)

1 reference

28 November 2017

0 references

3

1 reference

28 November 2017

Susan J Porter

1

1 reference

28 November 2017

Andrew A Somogyi

series ordinal

2

1 reference

28 November 2017

publication date

1 April 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

7

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

219-225

1 reference

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F135562102200120442

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F135562102200120442

Active drug metabolites. An overview of their relevance in clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F135562102200120442

Naltrexone biotransformation and incidence of subjective side effects: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F135562102200120442

Preclinical study of an oral controlled release naltrexone complex in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F135562102200120442

Effect of liver cirrhosis on the systemic availability of naltrexone in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F135562102200120442

10.1080/135562102200120442

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference